---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-24-000045"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:38:28.765348+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q2 revenue $182.4M, adjusted EPS $0.94; both up ~25-45% YoY

## Summary
- Net revenues $182.4M (Q2) vs $145.7M YoY; six-month $354.2M vs $285.7M.
- GAAP net income $37.9M ($0.73 diluted EPS) vs $26.1M ($0.49) YoY.
- Adjusted non-GAAP net income $48.7M ($0.94 diluted EPS) vs $34.8M ($0.65) YoY.
- CEO highlighted BAQSIMI as a leading portfolio driver amid transition to branded/biosimilar products.

## SEC filing metadata
- accession: 0001297184-24-000045
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718424000045/0001297184-24-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718424000045/amph-20240807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-24-000045
- JSON: https://secwatch.observer/filing/0001297184-24-000045.json
- Plain text: https://secwatch.observer/filing/0001297184-24-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.